Effects of atorvastatin and simvastatin on atrial plateau currents

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 5, 2007, Pages 931-945

  Vaquero, M ^a   Caballero, R ^a   Gomez R ^a   Nunez L ^a   Tamargo, J ^a   Delpon E ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Atorvastatin; Calcium channels; Cardiac action potentials; Kv1.5; Kv4.3; Simvastatin; Statins

Indexed keywords

ATORVASTATIN; CALCIUM CHANNEL L TYPE; QUINIDINE; SHAKER POTASSIUM CHANNEL; SHAL POTASSIUM CHANNEL; SIMVASTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; FEMALE; HAMSTER; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; KINETICS; MALE; MOUSE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; WHOLE CELL;

ACTION POTENTIALS; ANIMALS; CELL SEPARATION; CHO CELLS; CRICETINAE; CRICETULUS; HEART VENTRICLES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KV1.5 POTASSIUM CHANNEL; MALE; MEMBRANE POTENTIALS; MICE; MYOCYTES, CARDIAC; PYRROLES; SHAL POTASSIUM CHANNELS; SIMVASTATIN;

CRICETULUS GRISEUS;

EID: 34247569928     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.03.807     Document Type: Article

References (44)

1. Cheung B.M., Lauder I.J., Lau C.P., and Kumana C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. 57 (2004) 640-651
2. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
3. Bonetti P.O., Lerman L.O., Napoli C., and Lerman A. Statin effects beyond lipid lowering-Are they clinically relevant?. Eur. Heart J. 24 (2003) 225-248
4. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) III39-III43
5. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118
6. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol. 92 (2003) 1343-1345
7. Young-Xu Y., Jabbour S., Goldberg R., Blatt C.M., Graboys T., Bilchik B., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol. 92 (2003) 1379-1383
8. Lee T.M., Lin M.S., Chou T.F., Tsai C.H., and Chang N.C. Effect of pravastatin on left ventricular mass by activation of myocardial K ATP channels in hypercholesterolemic rabbits. Atherosclerosis 176 (2004) 273-278
9. 2+ channel activity and uncouples excitation from contraction in cardiac cells in culture. Proc. Natl. Acad. Sci. 83 (1986) 8007-8011
10. Tamargo J., Caballero R., Gómez R., Valenzuela C., and Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 62 (2004) 9-33
11. Nerbonne J.M., and Kass R.S. Molecular physiology of cardiac repolarization. Physiol. Rev. 85 (2005) 1205-1253
12. Mason P.R., Walter M.F., Day C.A., and Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am. J. Cardiol. 96 (2005) 11F-23F
13. Istvan E.S., and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 (2001) 1160-1164
14. Núñez L., Vaquero M., Gómez R., Caballero R., Mateos-Cáceres P., Macaya C., et al. Nitric oxide blocks hKv1.5 channel by S-nitrosylation and by a cyclic GMP-dependent mechanism. Cardiovasc. Res. 72 (2006) 80-89
15. + currents. Circulation 101 (2000) 1199-1205
16. Caballero R., Moreno I., González T., Valenzuela C., Tamargo J., and Delpón E. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc. Res. 56 (2002) 104-117
17. Moreno I., Caballero R., González T., Arias C., Valenzuela C., Iriepa I., et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J. Pharmacol. Exp. Ther. 304 (2003) 862-873
18. + currents in adult mouse ventricle. J. Physiol. 559 (2004) 103-120
19. + channels. J. Biol. Chem. 279 (2004) 394-400
20. + channel. Role of S6 in antiarrhythmic drug binding. Circ. Res. 78 (1996) 1105-1114
21. Weiss J.N. The Hill equation revisited: uses and misuses. FASEB J. 11 (1997) 835-841
22. Decher N., Kumar P., González T., Pirard B., and Sanguinetti M.C. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol. Pharmacol. 70 (2006) 1204-1211
23. Gerber R., Ryan J.D., and Clark D.S. Cell-based screen of HMG-CoA reductase inhibitors and expression regulators using LC-MS. Anal. Biochem. 329 (2004) 28-34
24. Simon S.A., and McIntosh T.J. Depth of water penetration into lipid bilayers. Methods Enzymol. 127 (1986) 511-521
25. Starke-Peterkovic T., Turner N., Vitha M.F., Waller M.P., Hibbs D.E., and Clarke R.J. Cholesterol effect on the dipole potential of lipid membranes. Biophys. J. 90 (2006) 4060-4070
26. Maguy A., Hebert T.E., and Nattel S. Involvement of lipid rafts and caveolae in cardiac ion channel function. Cardiovasc. Res. 69 (2006) 798-807
27. Cruz S.L., Orta-Salazar G., Gauthereau M.Y., Millán-Pérez Peña L., and Salinas-Stefanon E.M. Inhibition of cardiac sodium currents by toluene exposure. Br. J. Pharmacol. 140 (2003) 653-660
28. Gauthereau M.Y., Salinas-Stefanon E.M., and Cruz S.L. A mutation in the local anaesthetic binding site abolishes toluene effects in sodium channels. Eur. J. Pharmacol. 528 (2005) 17-26
29. 2+ channel function by volatile organic solvents. J. Pharmacol. Exp. Ther. 315 (2005) 1109-1118
30. 2+ channels expressed in HEK-293 cells. Anesthesiology 103 (2005) 1156-1166
31. 2+ channels of reticular thalamic neurons and recombinant Ca(v)3.3 channels. Br. J. Pharmacol. 144 (2005) 59-70
32. Li J., and Correa A.M. Kinetic modulation of HERG potassium channels by the volatile anesthetic halothane. Anesthesiology 97 (2002) 921-930
33. + channel by acting at the extracellular side of the ionic pore. Anesthesiology 99 (2003) 1340-1345
34. + channels toward halothane is essentially determined by the C terminus. J. Biol. Chem. 279 (2004) 34240-34249
35. Feron O., Dessy C., Desager J.P., and Balligand J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103 (2001) 113-118
36. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer A.T., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 300-305
37. Cilla Jr. D.D., Whitfield L.R., Gibson D.M., Sedman A.J., and Posvar E.L. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther. 60 (1996) 687-695
38. Desager J.P., and Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31 (1996) 348-371
39. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc. Res. 62 (2004) 105-111
40. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
41. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219-226
42. Blaauw Y., Gogelein H., Tieleman R.G., van Hunnik A., Schotten U., and Allessie M.A. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110 (2004) 1717-1724
43. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110 (2004) 2299-2306
44. Pandit S.V., Berenfeld O., Anumonwo J.M., Zaritski R.M., Kneller J., Nattel S., et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys. J. 88 (2005) 3806-3821